Post-marketing surveillance, also known as Phase IV clinical trials, is crucial for monitoring the long-term safety and effectiveness of approved cancer drugs. This ongoing process helps identify rare or delayed side effects that may not have been apparent in earlier trials. Regulatory agencies and healthcare professionals use this information to update treatment guidelines and ensure patient safety.
